Trial Profile
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2014
Price :
$35
*
At a glance
- Drugs NAB 001 (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Promius Pharma
- 21 Apr 2014 New trial record